On May 2, 2018, Novartis s Sandoz announced that it received a complete response letter (CRL) from FDA in response to the biologics license application (BLA) for the company s proposed rituximab biosimilar, which references Roche s Rituxan/MabThera (rituximab). Rituximab made CHF 7.3 billion (USOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.